Document is current
Any future updates will be listed below
-
Authors
Zhang, Qiong
Chen, Huicheng
Cun, Jintao
Liu, Qianqian
Wang, Hao
Jiang, Luxi
Hu, Shubo
Wang, Hongkun
Wang, Jingxin
Xu, Jian
Shi, Jinyue
Sun, Fangyuan
Xiong, Xianlang
Liang, Zhen
Yu, Yuansong
Du, Yuanyuan
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (T2322026)
Talent Plan of Shanghai Branch, Chinese Academy of Sciences (CASSHB-QNPD-2023-026)
International Partnership Program of the Chinese Academy of Sciences (nullGJHZ2024145FN)
Yunnan Provincial Xingdian Talent Support Program (XDYC-MY-2022-0059)
- License Information
-
More Information
Article History
Received: 3 May 2025
Accepted: 19 November 2025
First Online: 1 December 2025
Declarations
:
: All work with human embryos and hESC derivation was approved by the Medical Ethics Committee of Affiliated Hospital of Yunnan University. Title of the approved project: Establishment of human embryonic stem cell lines using clinically surplus and discarded blastocysts generated by in vitro fertilization. Approval number: 2023224. Date of approval: September 7, 2023. Informed consent was obtained from all couples who donated their embryos for the present study. All animal experiments were approved by the Animal Ethics Committee of Hangzhou Institute of Medicine, Chinese Academy of Sciences and conducted in accordance with the guidelines. Title of the approved project: In vivo evaluation of tumorigenic capacity of different pluripotent stem cell states. Approval number: AP2024-10-0307. Date of approval: October 31, 2024.
: All authors confirm their consent for publication.
: The authors declare no competing interests.
